PMID- 1374454
OWN - NLM
STAT- MEDLINE
DCOM- 19920610
LR  - 20231213
IS  - 0197-8357 (Print)
IS  - 0197-8357 (Linking)
VI  - 12
IP  - 2
DP  - 1992 Apr
TI  - Prolonged interferon-gamma application by subcutaneous infusion in cancer 
      patients: differential response of serum CD14, neopterin, and monocyte HLA class 
      I and II antigens.
PG  - 103-11
AB  - This study reports on biological response modification induced by prolonged 
      continuous subcutaneous (s.c.) infusion of recombinant interferon-gamma 
      (rIFN-gamma) with particular attention to changes of soluble CD14. This 
      glycoprotein with an unknown function is derived from myeloid cells carrying 
      membrane CD14, which is the receptor for lipopolysaccharide (LPS)-LPS-binding 
      protein (LBP) complexes. Fifteen metastatic cancer patients received weekly 
      escalating doses of rIFN-gamma starting at either 50 or 100 micrograms/24 h and 
      increasing up to 400 micrograms/24 h for a median duration of 6 weeks. The 
      maximum tolerated dose was higher (200 micrograms/24 h) with the lower (50 
      micrograms/24 h) starting dose. Biological activity of rIFN-gamma was evaluated 
      by weekly measurements of CD14, neopterin, and beta 2-microglobulin 
      concentrations in serum as well as monocyte HLA class I and II antigen expression 
      and tumor cytotoxicity. Serum IFN-gamma concentrations increased 20-fold within 4 
      weeks of therapy. The levels were correlated to the mean dose (r = 0.95, p less 
      than 0.05). Among the biological markers, two patterns were observed. First, 
      serum CD14 concentration and expression of monocyte HLA class II antigens 
      increased significantly during the first week, and marker expression correlated 
      with serum IFN-gamma levels (p less than 0.05); CD14 and HLA class II antigens 
      thereafter returned to pretreatment levels within 4 weeks of therapy despite 
      persistently elevated serum IFN-gamma concentrations. Second, serum neopterin and 
      beta 2-microglobulin concentrations as well as monocyte HLA class I expression 
      also increased significantly within the first week, but remained elevated 
      thereafter without any further dose relationship.(ABSTRACT TRUNCATED AT 250 
      WORDS)
FAU - Landmann, R
AU  - Landmann R
AD  - Department of Research and Internal Medicine, University Hospital, Basel, 
      Switzerland.
FAU - Ludwig, C
AU  - Ludwig C
FAU - Wesp, M
AU  - Wesp M
FAU - Fisscher, A
AU  - Fisscher A
FAU - Obrist, R
AU  - Obrist R
FAU - Knusli, C
AU  - Knusli C
FAU - Denz, H
AU  - Denz H
FAU - Obrecht, J P
AU  - Obrecht JP
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Interferon Res
JT  - Journal of interferon research
JID - 8100396
RN  - 0 (Antigens, CD)
RN  - 0 (Antigens, Differentiation, Myelomonocytic)
RN  - 0 (HLA Antigens)
RN  - 0 (Lipopolysaccharide Receptors)
RN  - 0 (Recombinant Proteins)
RN  - 0 (beta 2-Microglobulin)
RN  - 0 (Biopterins)
RN  - 670-65-5 (Neopterin)
RN  - 82115-62-6 (Interferon-gamma)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Antigens, CD/*blood
MH  - Antigens, Differentiation, Myelomonocytic/*blood
MH  - Biopterins/*analogs & derivatives/blood
MH  - Drug Administration Schedule
MH  - HLA Antigens/*blood
MH  - Humans
MH  - Infusion Pumps
MH  - Injections, Subcutaneous
MH  - Interferon-gamma/*administration & dosage/adverse effects/blood/therapeutic use
MH  - Lipopolysaccharide Receptors
MH  - Middle Aged
MH  - Monocytes/*immunology
MH  - Neoplasms/immunology/*therapy
MH  - Neopterin
MH  - Recombinant Proteins
MH  - beta 2-Microglobulin/analysis
EDAT- 1992/04/01 00:00
MHDA- 1992/04/01 00:01
CRDT- 1992/04/01 00:00
PHST- 1992/04/01 00:00 [pubmed]
PHST- 1992/04/01 00:01 [medline]
PHST- 1992/04/01 00:00 [entrez]
AID - 10.1089/jir.1992.12.103 [doi]
PST - ppublish
SO  - J Interferon Res. 1992 Apr;12(2):103-11. doi: 10.1089/jir.1992.12.103.